The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.80
Ask: 3.84
Change: 0.09 (2.43%)
Spread: 0.04 (1.053%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.71
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Approval of Harpinαβ in Belgium

22 Apr 2024 07:00

RNS Number : 3821L
Plant Health Care PLC
22 April 2024
 

22 April 2024

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

 Approval for Sale of Harpinαβ Granted in Belgium

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce that Harpinαβ, the Company's core, high-value fertilizer product with biostimulant properties, has successfully achieved registration in Belgium. This is a major operational milestone for the Company and permits immediate sales of Harpinαβ in Belgium. 

Following the initial regulatory approval in France in October 2022, Plant Health Care has pursued approvals to expand the use of Harpinαβ across Europe. Mutual recognition was achieved in Poland and Spain in 2023 and Portugal in February of 2024. With the granting of the derogation, Belgium is the next EU country to authorize sales of Harpinαβ. Europe is the world's largest market for sustainable agriculture with annual sales of over $2 billion.

Harpinαβ is a recombinant protein that acts as a powerful biostimulant, improving the yield and quality of crops. Plant Health Care is launching Harpinαβ for use in European potato production, followed by fruit and vegetable crops. Belgium is one of the leading agricultural producers in the EU, and the Belgium potato harvest in 2023 was 4.85 million tons from 96,000 planted hectares.

 

The Company sells Harpinαβ through specialist distributors around the world. Field trials are ongoing with interested distributors to observe the results of Harpinαβ on treated potato plants and the Company plans to select a distributor for the European market prior to the end of 2024.

 

Angel Marin, Director EMEAA for Plant Health Care, said: ‟It has been a long-term goal of the Company to expand the use of its core product, Harpinαβ across Europe's biggest agricultural markets. The authorization to begin sales in Belgium brings us one-step closer and the Company expects to select our distribution partner for the EU countries by the end of the year. Harpinαβ is an environmentally friendly, and proven protein technology which improves plant growth and development resulting in higher quality, yields and long-term storage stability, which are critical as the world seeks to address food security."

 

# # # 

 

For further information, please contact:

Plant Health Care plc Jeff Tweedy, CEO

 

Tel: +1 919 926 1600

Cavendish Capital Markets Limited - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, sugarcane, potatoes, rice, and wheat, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors, and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGPUQCCUPCGWB
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.